Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2015

View Archived Issues

Ferring acquires assets of orthopedic biomaterial developer BioSET

Propanc starts animal studies of proteolytic proenzymes for cancer

RepliCel Life Sciences submits clinical trial application for RCS-01

ZP-GA-1 shows similar PK characteristics to native glucagon

Marathon sells non-strategic products to focus on treatments for rare diseases

Merck Serono and Sysmex Inostics announce opening of liquid biopsy RAS biomarker testing center

Cyclenium Pharma and Fundacion Medina form drug discovery agreement

Xeris Pharmaceuticals presents comparative PK/PD study of G-Pump and GlucaGen

Plasma kallikrein inhibitors disclosed in Kalvista Pharmaceuticals patent

U. S. researchers develop recombinant N. meningitidis factor H binding proteins

Isis reports chemically modified ssASOs targeting ataxin-3

Galapagos patents CFTR modulators

Takeda patent reveals prokineticin PKR1 receptor antagonists

New orexin receptor antagonists disclosed by Merck & Co.

Saroglitazar reverses biochemical manifestations of metabolic syndrome

Nobelpharma launches Zanosar i.v. infusion in Japan

Axitinib shows activity against mutant BCR-ABL1 leukemia

Eisai's phase III trial of eribulin in soft tissue sarcoma meets primary endpoint

AstraZeneca and Orca Pharmaceuticals partner to discover ROR gamma inhibitors

Isis Pharmaceuticals announces phase I results for prekallikrein inhibitor for HAE

Phase I results indicate ALKS-7106 does not warrant further development

Neurotrope releases topline results from phase IIa trial of bryostatin 1 for Alzheimer's disease

First patient treated in trial of Renevia in HIV-associated lipoatrophy

Eisai reports results from phase II trial of lenvatinib in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...